That makes no sense. What connection are you trying to make? SmallCapVoice is widely used in OTC market. They are a very respectable company.

Michael James Enterprises, Inc. Brand Ambassador, Dr. Kristina Kincaid Featured in Exclusive Interview with SmallCapVoice.com
http://smallcapvoice.com/blog/10-31-16-smallcapvoice-interview-with-michael-james-enterprises-inc-mjtv/

$MJTV's new product, "Voluptas"!

She's not practicing medicine! Stop making false accusations!

She has a Doctorate Degree! Any educated person knows that gives you the title of Doctor. You think college professors are all M.D.'s?

MJTV Files For Trademark of VOLUPTAS The New Neuroceutical Female Sexual Arousal Booster And The Sexuality Project Series Of Classes And Workshops

WHIPPANY, NJ--(Marketwired - Oct 26, 2016) - Michael James Enterprises, Inc. (OTCQB: MJTV), is pleased to report that it just filed for trademark protection for its female sexual arousal enhancer - Voluptas. Dr. Kristina Kinkaid will also begin a series of Voluptas - The Sexuality Project classes, conferences and workshops.
The Voluptas Sexuality Project is initially expected to run once a month and will begin traveling to cities throughout the United States in the first half of 2017 and eventually Western Europe. The date of the first workshop is to be set in the next few weeks, but just from word of mouth is being close to being sold out. MJTV is exploring the idea of increasing the size of each workshop.
MJTV is currently working on its packaging and artwork for the Voluptas product as well as finalizing the exact product and manufacturing costs. MJTV is still on course to have the Voluptas product ready for market in the first quarter of 2017. The Voluptas Sexuality Project series is starting soon to begin the pre-branding of the Voluptas product.
Brand Ambassador, Dr. Kristina Kincaid, stated, "I gave out samples of Voluptas to several of my friends (former Victoria Secret models) and that night and even the next morning they were astonished with the results. Additionally, the response has been incredible so far just in preparing for the start of our Voluptas Sexuality Project series and we have not even begun to do any marketing. I am so excited to be a part of this because it is just so explosive and exciting."
Safe Harbor Statement
This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.
CONTACT INFORMATION
Michael James Enterprises, Inc.
760 Route 10 West, Suite 203
Whippany, NJ 07981
908-204-0004

It's actually up 400% to 500% since your post!

What? Your "felony" comment is absurd and purposely meant to mislead people. She's not practicing medicine. Her complete list of education is listed and is very transparent. She is not a medical doctor and never claimed to be. A doctor is a person who holds a "doctorate" degree, which she does. It does not mean medical doctor as such there is no M.D. after her name.

She is a Brand Ambassador, not a member of a scientific advisory board. Brand Ambassador's are reputable professionals from specific industries who endorse products they believe in. Medical doctor again has no relevance here.

Far stretch, but no relevance to Dr. Kincaid, a reputable professional in the industry of women's sexuality, and her new ambassadorship with MJTV for their new product.

World Renowned Sexologist Dr. Kristina Kincaid Becomes Brand Ambassador for MJTV's New Neuroceutical Female Arousal Booster

DOWNLOAD AS PDF September 23, 2016
WHIPPANY, NJ -- (Marketwired) -- 09/23/16 -- Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that Dr. Kristina Kincaid signed a binding letter of intent to become the Brand Ambassador for the female sexual arousal enhancer. The final definitive agreement should be signed in the next week.

Dr. Kincaid is the Director of The Institute of Integral Evolutionary Tantra in New York City and is the Chairperson and a co-creator of the Outrageous Love Project. She has been on the Faculty of The Institute of Core Energetics for the last ten years. She holds an M.A. and Doctorate in Energy Medicine from Holos University. A graduate of the Institute of Core Energetics and the prestigious Barbara Brennan School of Healing, she also earned a B.A. in Anthropology from the University of Texas, Austin.

Kristina is a leading authority on women's sexuality, respected among her peers for her expertise based on extensive study and experience. She has worked with women for over sixteen years, co-creating a body of work called The Erotic Goddess. She is currently co-authoring two books, the first; 'A Return To Eros: On Sex, Love and Living Erotically In Every Dimension Of Your Life', the second is titled 'Sexually Incorrect: The Seven Levels of Sexing, A Radically Awake, Alive and Erotic Guide To The Sexual'. Both books are to be published in the spring of 2017.

MJTV Brand Ambassador, Dr. Kincaid, stated, "When presented this opportunity I engulfed myself in an extensive due diligence of the active ingredients and came away completely astonished by what I believe to be just incredible results women have experienced. I am very proud to be a part of this project that should allow many women to take control of their own sexuality. MJTV management and I are diligently working on the branding materials, artwork, packaging and marketing plan to roll this product out in the near future."

Safe Harbor Statement This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.

CONTACT INFORMATION:
Michael James Enterprises, Inc.
760 Route 10 West, Suite 203
Whippany, NJ 07981
908-204-0004

Pazoo moved months ago

Michael James Enterprises Creates New Line of Neuroceuticals and Begins Development of New Website

WHIPPANY, NJ--(Marketwired - Sep 21, 2016) - Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that it will be adding a new line of product offerings as Neuroceuticals to the already existing line of Pharmaceuticals. MJTV also has a new web page up www.mjbiotech.com. The website will be expanded and further developed over the coming weeks.

MJTV will begin with two new products under its neuroceutical line. One will be offered to help with sleep while the other offering will be for women as a sexual arousal enhancer. Patents and trademarks will be filed very soon at which time the specific products will be announced. Each product will have a brand ambassador and will be sold via direct response through all mediums and through any distribution channel that makes sense.

Both products are expected to be available in the first quarter of 2017 and possibly sooner. Inventory and ongoing supply for the ingredients is readily available and can easily be scaled up as sales begin to accelerate. The active ingredients are not directed at the physical or cardiovascular systems. Instead, they are directed at the Neurological system hence the name Neuroceutical.

James Farinella, CEO of Michael James Enterprises, stated, "We expect very big things from these two new neuroceutical therapeutic offerings. We are not the typical biotech company. We will look to have two or three different lines from Neutriceuticals, Neuroceuticals to Pharmaceuticals. Pharmaceuticals take a much longer period of time to bring to market, while the other two lines can be brought to market over the counter almost immediately providing for a revenue generating stable company environment.

" Safe Harbor Statement This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.

CONTACT INFORMATION: Michael James Enterprises, Inc. 760 Route 10 West, Suite 203 Whippany, NJ 07981 908-204-0004 Wertpapier: Michael James Enterprises Themen: WHI

Michael James Enterprises Creates New Line of Neuroceuticals and Begins Development of New Website

WHIPPANY, NJ--(Marketwired - Sep 21, 2016) - Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that it will be adding a new line of product offerings as Neuroceuticals to the already existing line of Pharmaceuticals. MJTV also has a new web page up www.mjbiotech.com. The website will be expanded and further developed over the coming weeks.

MJTV will begin with two new products under its neuroceutical line. One will be offered to help with sleep while the other offering will be for women as a sexual arousal enhancer. Patents and trademarks will be filed very soon at which time the specific products will be announced. Each product will have a brand ambassador and will be sold via direct response through all mediums and through any distribution channel that makes sense.

Both products are expected to be available in the first quarter of 2017 and possibly sooner. Inventory and ongoing supply for the ingredients is readily available and can easily be scaled up as sales begin to accelerate. The active ingredients are not directed at the physical or cardiovascular systems. Instead, they are directed at the Neurological system hence the name Neuroceutical.

James Farinella, CEO of Michael James Enterprises, stated, "We expect very big things from these two new neuroceutical therapeutic offerings. We are not the typical biotech company. We will look to have two or three different lines from Neutriceuticals, Neuroceuticals to Pharmaceuticals. Pharmaceuticals take a much longer period of time to bring to market, while the other two lines can be brought to market over the counter almost immediately providing for a revenue generating stable company environment.

" Safe Harbor Statement This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.

CONTACT INFORMATION: Michael James Enterprises, Inc. 760 Route 10 West, Suite 203 Whippany, NJ 07981 908-204-0004 Wertpapier: Michael James Enterprises Themen: WHI

I'm staying away till after the election. But I'm a wuss sometimes with these oil plays :). Good luck!

I can see it hitting $2.00 early next week. Probably see a lot of high volume and day trades for he next week

I have never been paid or compensated by Pazoo in any way! Please do not say that. I am a long time investor who does a great deal of due diligence and I attempt to share that information with other investors so they can make informed decisions. Please refrain from spreading your false paid pumper rumors! I've had enough of it.

In their defense, it's in their interest to protect their company. Still, I would also like to see decriminalization

Pharma's like this are the future as long as marijuana isn't decriminalized or reclassified

It's hard to give up that hope

Glad we passed Phase 2 of Clinical trials. $NVAX got destroyed today!

James Farinella did NOT make this video. I'd have to guess some disgruntled investor made it and posted it under his name, but who knows. Either way... a couple guys are now trolling the boards trying to discredit him by posting the link to this FAKE video.

Great news!

Wrong! Someone posted it using his name! He did NOT post or make any such video.

$MJTV - Now to put this in perspective, imagine if you could take a Dronabinol capsule in lieu of using one of these cumbersome and noisy devices! We are entering a huge market with great demand!

http://www.pressreleaserocket.net/sleep-apnea-devices-market-to-reach-7-9-billion-by-2022-grand-view-research-inc/

Exactly!!! Another PR with unbelievable news! This is their 2nd Dronabinol based product in their pipeline with more to come! This company doing it right...pursue the "legal" alternatives to marijuana and pursue it aggressively!

Once again...that is not what par value means. Here is the education lesson again:

There are an increasing number of states that do not require you to set a Par Value on your stock, but assuming you are a Delaware Corporation, you will be advised to set a par value to minimize your potential Delaware Franchise Taxes. The par value has no impact on the “valuation” of your company as viewed by potential investors nor the future potential of your business. It is a meaningless number these days, so set it at a level that truly makes it meaningless and avoid paying a lot of money for your founders shares in the process. Essentially, allowing founders of companies to pay less taxes on their original shares.

Uh...that now how that works or what that means. There are an increasing number of states that do not require you to set a Par Value on your stock, but assuming you are a Delaware Corporation, you will be advised to set a par value to minimize your potential Delaware Franchise Taxes. The par value has no impact on the “valuation” of your company as viewed by potential investors nor the future potential of your business. It is a meaningless number these days, so set it at a level that truly makes it meaningless and avoid paying a lot of money for your founders shares in the process. Essentially, allowing founders of companies to pay less taxes on their original shares.

That video was not put out by Farinella. In fact, the person(s) who did put it out exposed themselves to libel. It was a poor and illegal attempt to slander his name. Additionally, Pazoo is not his company. He was only an investor...though a large investor.

Very true! There is huge potential with Dronabinol, especially with the DEA's decision to keep marijuana a Class I Controlled Substance!

$MJTV IN RECENT WEEKS!
1) ACQUIRED RIGHTS TO DRONABINOL FOR SLEEP APNEA
2) PARTNERED W/ HEALTH PARTNERS INSTITUTE FOR RESEARCH
3) ESTABLISHING A STRONG GROUP OF SCIENTIFIC ADVISORS

"While this is new to MJTV, there has already been much time and work already invested for the future success of our company with this venture. We will be bringing in the top medical and scientific minds to the company to ensure the highest likelihood of success for MJTV and its shareholders."

More great news! This company is coming together! Future looks very bright!

Michael James Enterprises Buys Assignment of Master Agreement to Work With HealthPartners Institute for Education and Research

DOWNLOAD AS PDF August 11, 2016
SHORT HILLS, NJ -- (Marketwired) -- 08/11/16 -- Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has purchased all rights title and interest to a master advising agreement. This master agreement with HealthPartners now entitles MJTV to work with William H. Frey, II, PhD., who is an expert in intranasal delivery.

One of the largest medical research and education centers in the Midwest, HealthPartners Institute, helps transform health care in the Midwest region and across the nation. As part of HealthPartners integrated care system, the Institute uses research and education to advance the Triple Aim of improving health, experience and affordability for their members, patients and the community at large. HealthPartners Institute conducts health services, survey-based, behavioral intervention, clinical and basic science research with collaborators within HealthPartners and around the world. Our research strengths include:

Child and maternal health
Chronic disease/diabetes
Clinical research
Critical care
Health economics
Mental health
Neurosciences/Alzheimer's and Parkinson's disease
Oncology
Oral health/dentistry
William H. Frey, II, PhD., will serve as one of MJTV's scientific advisors and provide scientific advising services on behalf of HealthPartners Institute. MJTV will retain all right and title to all documentation and work product from this relationship. MJTV expects to add many more top scientific and medical experts in the coming weeks and months building the highest quality minds to advise and work with MJTV.

Dr. William H. Frey, II is the Founder and Co-Director of the Alzheimer's Research Center at Regions Hospital, Professor of Pharmaceutics and faculty member in Neurology, Oral Biology and Neuroscience at the University of Minnesota and consultant to the pharmaceutical and biotechnology industry. Dr. Frey's non-invasive intranasal method for bypassing the blood-brain barrier to rapidly delivery and target therapeutic agents to the brain along the olfactory and trigeminal neural pathways while reducing systemic exposure and unwanted side effects has captured the interest of both pharmaceutical companies and neuroscientists.

James Farinella, CEO of Michael James Enterprises, stated, "While this is new to MJTV, there has already been much time and work already invested for the future success of our company with this venture. We will be bringing in the top medical and scientific minds to the company to ensure the highest likelihood of success for MJTV and its shareholders."

Safe Harbor Statement

This release contains forward-looking statements, which are made pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are commonly identified by words such as "would," "may," "will," "expects," and other terms with similar meaning. Forward-looking statements are based on current beliefs, assumptions and expectations and speak only as of the date of this release and involve risks and uncertainties that could cause actual results to differ materially from current expectations. We assume no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason.

Michael James Enterprises, Inc.
784 Morris Turnpike, Suite #334
Short Hills, NJ 07078
908-204-0004

Source: Michael James Enterprises, Inc.

Released August 11, 2016

Great opportunity to listen to $MJTV discuss the great news regarding their move to sign a purchasing agreement for the rights to Dronabinol. 1 of only 3 FDA Approved THC drugs!

http://www.moneytv.net/

Michael James Enterprises Signs Asset Purchase Agreement Acquiring All Rights and Intellectual Property for the Development of Dronabinol-Based Therapeutic Treatments for Sleep Disorders

DOWNLOAD AS PDF August 05, 2016
SHORT HILLS, NJ -- (Marketwired) -- 08/05/16 -- Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has entered into an Asset Purchase Agreement with RP Capital Group acquiring all of the rights and intellectual property to develop and bring to market therapeutic treatments for sleep disorders using Dronabinol as the base ingredient. Raj Pamnani, who recently joined the Board of Directors, brings to MJTV this promising already work in progress therapeutic treatment.

Dronabinol is the generic form of Marinol, a cannabinoid that was approved by the FDA to be prescribed by doctors in all 50 states back in 1985. Currently Dronabinol is used for cancer patients for nausea and aids patients to help keep up their weight. The University of Illinois, Chicago recently finished phase 2B clinical trials to treat sleep apnea utilizing Dronabinol with the results to be published in the next few weeks. If the results are what everyone expects them to be, it will be a major moment for the potential expanded use of Dronabinol for sleep disorders.

Prior to bringing these rights into MJTV, Mr. Pamnani, added in another active ingredient with the Dronabinol and conducted pre-clinical trials with very promising results. We feel this is a major improvement for treating sleep apnea above using just Dronabinol. MJTV will be working on additional formulations with the Dronabinol for other medical indications and applications moving forward.

James Farinella, CEO of Michael James Enterprises stated, "I had originally planned to bring this product into MJTV but wanted to have the clinical 2B trials completed first. This was always expected to be the main business of MJTV. We will now keep the acne treatment system in the private company and advance the business and get it closer to commercialization before considering bringing it into the fold."

"MJTV will now be adding a new product to the mix making the company a true Biotech."

Michael James Enterprises Appoints Raj Pamnani to the Board of Directors

DOWNLOAD AS PDF August 03, 2016
SHORT HILLS, NJ -- (Marketwired) -- 08/03/16 -- Michael James Enterprises, Inc. (OTCQB: MJTV) is pleased to report that MJTV has replaced Scott Weiner with Raj Pamnani, joining Gina Morreale and the Chairman of the Board, James M. Farinella. Mr. Pamnani has amassed a very impressive business track record bringing a wealth of relationships including, but not limited to, world renowned scientists and medical experts.

Mr. Pamnani has wealth of experience in the capital markets and focused on corporate finance, mergers and acquisitions, investment banking, and structuring bridge and mezzanine financings in the healthcare and information technology sectors. He served in corporate finance in New York at companies like Josephthal & Co. as Senior Vice-President and Merrill Lynch as Vice-President, where Mr. Pamnani managed over $70 million and has experience in negotiating and structuring private equity transactions.

Mr. Pamnani was instrumental in bringing several biotechnology companies public in the late 1980s and early 1990s, including Medarex, Zonagen, Texas Biotechnology, Ariad Pharmaceuticals, and SciClone Pharmaceuticals. He also has considerable business development experience. He has numerous international real estate and food related holdings, and served as a consultant to Citibank (Private Bank) in Singapore. Mr. Pamnani has a powerful international network of investors, entrepreneurs and others.

James Farinella, CEO of Michael James Enterprises, stated, "MJTV is truly blessed to have Raj join the board and bring his wealth of experience and talent. MJTV will now be adding a new product to the mix making the company a true Biotech."

SEC Has NO Charges Against Pazoo or Farinella Per the Article You Posted!

In my opinion, you're grasping at straws again! This has nothing to do with Pazoo and Farinella as there are not implicated in that at all per your article. They aren't even mentioned. You just added them to fake title in bold. This is strictly related to HEMP, Inc. Yes, Pazoo signed a consulting agreement with their subsidiary, Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC). The consulting was specific to the Industrial Hemp/Medical Marijuana Industry in the area of market awareness and marketing strategy, raising capital and finding funding sources, and general industry specific business guidance at the public level.
Remember...Several other reputable marijuana companies had the same consulting agreement, but Pazoo's was just days old. Once again...please show evidence. You can't post PR's related to another company and then say it's Pazoo's and Farinella fault. There is no correlation between them that you have shown.

SEC Has NO Charges Against Pazoo or Farinella Per the Article You Posted!

In my opinion, you're grasping at straws again! This has nothing to do with Pazoo and Farinella as there are not implicated in that at all per your article. They aren't even mentioned. You just added them to fake title in bold. This is strictly related to HEMP, Inc. Yes, Pazoo signed a consulting agreement with their subsidiary, Industrial Hemp and Medical Marijuana Consulting Company, Inc. (IHMMCC). The consulting was specific to the Industrial Hemp/Medical Marijuana Industry in the area of market awareness and marketing strategy, raising capital and finding funding sources, and general industry specific business guidance at the public level.
Remember...Several other reputable marijuana companies had the same consulting agreement, but Pazoo's was just days old. Once again...please show evidence. You can't post PR's related to another company and then say it's Pazoo's and Farinella fault. There is no correlation between them that you have shown.

All the article shows is that someone sent an unknown document and the FBI simply emailed back confirming receipt. We don't even know what the document is. There is no proof here or anywhere else that there is an active investigation against Pazoo or Farinella. So far, I'm just reading an article filled with hearsay, some false accusations (ex. YouTube) and no solid evidence of what the author is claiming.